Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17A | Q9UEE5 | 15/20 | 0.55 |
| ▸ | STK17B | O94768 | 10/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13348478 | 0.90 | CHEK1 (0.43) | STK17ASTK17BGLO1CHEK1FLT3 | |
| SCHEMBL13311035 | 0.86 | STK17A (0.74) | STK17ASTK17B | |
| SCHEMBL3450397 | 0.86 | STK17A (0.55) | STK17ASTK17BAXLCHEK1FLT3 | |
| Hydrochloric Acid SCHEMBL3345813 | 0.85 | STK17A (0.72) | STK17ASTK17B | |
| SCHEMBL13310814 | 0.85 | STK17A (0.57) | STK17ASTK17BMAPK1AXL | |
| SCHEMBL13310862 | 0.85 | STK17A (0.57) | STK17ASTK17BAXL | |
| SCHEMBL13310813 | 0.85 | STK17A (0.57) | STK17ASTK17BAXLCHEK1 | |
| SCHEMBL13310818 | 0.83 | STK17A (0.54) | STK17ASTK17BMAPK1AXL | |
| SCHEMBL13310837 | 0.83 | STK17A (0.54) | STK17ASTK17BMAPK1AXL | |
| SCHEMBL3448722 | 0.82 | STK17A (0.54) | STK17ASTK17BMAPK1AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | STK17A 1984/4885STK17B 2457/4885MAPK1 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.